Genmab — Februar 2025

[lahn1]

De prædiker vel blot det der er størst sandsynlighed for. Så er chancen for ikke at tabe ansigt størst.

[w]

Hvorfor overhovedet gi begrundelsen “manglende interesse”.

[Raun]

Der kan kun være en forklaring på den slags gentagelser... - De er blandt de såkaldte spekulanter.... Lur mig de kommer til at tjene kassen.... Ellers synes jeg da bare de skulle have shortet den hver gang de er kommet med disse udmeldinger.... Nåh nej, det virker jo ikke til at skurkene vil tjene penge...

[royal]

For filan. Der er vel ikke nogen der forventer løbende kommentering indenfor de 60 dage?

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[KWC]

RAUN 22.39 Short eller ej ...

[KWC]

Så havde Novod go grund til skepsis gennem tiden.. Det er da tydeligt nu.. Vi er i et sort hul,
hvor ingen vil kaste penge ind i..

[KWC]

Som Novod sagde...Døde penge.. Men ikke sjovt at se på ...

[LP90]

Godmorgen

[bongobob]

Not so fun fact: Der er udstedt 20mill aktier siden 2012 og det stopper ikke. Buyback sletter ikke aktier. https://www.macrotrends.net/stocks/charts/GNMSF/genmab/shares-outstanding

[bongobob]

Genmab bliver ikke en X10 herfra, der er for mange med ved bordet

[Sukkeralf]

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investig

Yahoo Finance (finance.yahoo.com)

[E_L]

i didn't realise they were this far in children already. Let's hope Novo can speed up the regulatory submission a bit. "At week 26, 98% of caregivers said they preferred Mim8 to prior treatment, of which 73% said they ‘very strongly’ preferred Mim8 to prior treatment."

[E_L]

Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect https://www.fiercebiotech.com/biotech/novo-adds-pediatric-data-bulging-bag-evidence-near-approval-hemophilia-prospect

[Aaanditsgone]

"the prior treatment" being Hemlibra, or..?

[E_L]

whatever they were on before starting this trial; it is not further specified in this data; but as Hemlibra is such a dominant player in this market, i would think your guess would be correct for most patients

[Aaanditsgone]

Time for an upward adjustment of Mim8 peak sales estimates, perhaps?

[lahn1]

Er det grunden til at de først sender ansøgningen i H2 2025. Det var vist tidligere nu de skulle have sendt ansøgningen.

[lahn1]

At de vil have børn med i godkendelsen fra start.